Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
AbCellera Biologics Inc. (ABCL)
A forensic read on AbCellera Biologics Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
4.7
Altman Z-score
Watch
Earnings quality
2
Forensic signals
-14.9%
ROE
$2.0B
Market cap
AbCellera Biologics Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 4.7, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-15%Return on invested capital.Return on invested capital is -15% and slipping from 14% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
74% of revStock-based comp load.Stock-based compensation ran 74% of revenue in FY2025 — about $0.19 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-194.9%
Debt / Equity0.00x
Free Cash Flow$-174.1M
Latest Revenue$75.1M
Return on Equity-15.1%
Revenue Growth YoY+160.6%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on AbCellera Biologics Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about ABCL's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown